Dendrimer-Entrapped Gold Nanoparticles as Potential CT Contrast Agents for Localizing Sentinel Lymph Node via Indirect CT Lymphography on Rabbit Model

Shi, Fang; Yang, Yue; Chen, Jian; Sha, Yan; Shu, Yilai; Wu, Haitao

doi:10.1155/2018/1230151

Cited by 4 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For reviewing the application of CT lymphography in early-stage OSCC, the systematic literature search led to retrieval of 112 PubMed indexed articles for CT lymphography, of which 17 were considered relevant [ 26 , 27 , 28 , 29 , 30 , 31 , 40 , 41 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 ]. Of these 17 articles, 11 were animal studies [ 40 , 41 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 ]. Cross-reference did not lead to any additional relevant articles.…”

Section: Resultsmentioning

confidence: 99%

“…For reviewing the application of CT lymphography in early-stage OSCC, the systematic literature search led to retrieval of 112 PubMed indexed articles for CT lymphography, of which 17 were considered relevant [26][27][28][29][30][31]40,41,[64][65][66][67][68][69][70][71][72]. Of these 17 articles, 11 were animal studies [40,41,[64][65][66][67][68][69][70][71][72].…”

Section: Ct Lymphographymentioning

confidence: 99%

See 1 more Smart Citation

New Developments in Imaging for Sentinel Lymph Node Biopsy in Early-Stage Oral Cavity Squamous Cell Carcinoma

Mahieu

Maar

Nieuwenhuis

et al. 2020

Cancers

View full text Add to dashboard Cite

Sentinel lymph node biopsy (SLNB) is a diagnostic staging procedure that aims to identify the first draining lymph node(s) from the primary tumor, the sentinel lymph nodes (SLN), as their histopathological status reflects the histopathological status of the rest of the nodal basin. The routine SLNB procedure consists of peritumoral injections with a technetium-99m [99mTc]-labelled radiotracer followed by lymphoscintigraphy and SPECT-CT imaging. Based on these imaging results, the identified SLNs are marked for surgical extirpation and are subjected to histopathological assessment. The routine SLNB procedure has proven to reliably stage the clinically negative neck in early-stage oral squamous cell carcinoma (OSCC). However, an infamous limitation arises in situations where SLNs are located in close vicinity of the tracer injection site. In these cases, the hotspot of the injection site can hide adjacent SLNs and hamper the discrimination between tracer injection site and SLNs (shine-through phenomenon). Therefore, technical developments are needed to bring the diagnostic accuracy of SLNB for early-stage OSCC to a higher level. This review evaluates novel SLNB imaging techniques for early-stage OSCC: MR lymphography, CT lymphography, PET lymphoscintigraphy and contrast-enhanced lymphosonography. Furthermore, their reported diagnostic accuracy is described and their relative merits, disadvantages and potential applications are outlined.

show abstract

Section: Resultsmentioning

confidence: 99%

“…For reviewing the application of CT lymphography in early-stage OSCC, the systematic literature search led to retrieval of 112 PubMed indexed articles for CT lymphography, of which 17 were considered relevant [26][27][28][29][30][31]40,41,[64][65][66][67][68][69][70][71][72]. Of these 17 articles, 11 were animal studies [40,41,[64][65][66][67][68][69][70][71][72].…”

Section: Ct Lymphographymentioning

confidence: 99%

New Developments in Imaging for Sentinel Lymph Node Biopsy in Early-Stage Oral Cavity Squamous Cell Carcinoma

Mahieu

Maar

Nieuwenhuis

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Even so, modifications of oil-based iodinated contrast media could increase the degree of lymphatic drainage while still allowing for long-term retention in lymph nodes, potentially improving SLN detection by CTL [ 16 , 31 ]. Alternatively, other radiocontrast agents (e.g., Nanotrast-CF800 entrapped gold nanoparticles) have shown their potential for SLN mapping using CTL in animal studies [ 32 , 33 , 34 ]. These modified radiocontrast agents may enhance the utility of CTL for SLN mapping but have yet to be investigated in human studies.…”

Section: Discussionmentioning

confidence: 99%

CT Lymphography Using Lipiodol® for Sentinel Lymph Node Biopsy in Early-Stage Oral Cancer

Mahieu

Donders

Dankbaar

et al. 2022

JCM

View full text Add to dashboard Cite

This study evaluated sentinel lymph node (SLN) identification with CT lymphography (CTL) following peritumoral administration of Lipiodol® relative to conventional 99mTc-nanocolloid lymphoscintigraphy (including SPECT/CT) in 10 early-stage oral cancer patients undergoing SLN biopsy. Patients first underwent early dynamic and static scintigraphy after peritumoral administration of 99mTc-nanocolloid. Subsequently, Lipiodol® was administered at the same injection sites, followed by fluoroscopy and CT acquisition. Finally, late scintigraphy and SPECT/CT were conducted, enabling the fusion of late CTL and SPECT imaging. The next day, designated SLNs were harvested, radiographically examined for Lipiodol® uptake and histopathologically assessed. Corresponding images of CT, 99mTc-nanocolloid lymphoscintigraphy and SPECT/late CTL fusion were evaluated. 99mTc-nanocolloid lymphoscintigraphy identified 21 SLNs, of which 7 were identified with CTL (33%). CTL identified no additional SLNs and failed to identify any SLNs in four patients (40%). Out of six histopathologically positive SLNs, two were identified with CTL (33%). Radiographic examination confirmed Lipiodol® uptake in seven harvested SLNs (24%), of which five were depicted with CTL. CTL using Lipiodol® reached a sensitivity of 50% and a negative predictive value (NPV) of 75% (median follow-up: 12.3 months). These results suggest that CTL using Lipiodol® is not a reliable technique for SLN mapping in early-stage oral cancer.

show abstract

“…The use of nanoparticles offers opportunities for improved image guidance. In one study, Fang et al injected dendrimer-entrapped gold nanoparticles into rabbit models and used CT imaging to identify the presence of cervical sentinel lymph nodes, leading to statistically significant enhancements in signal and a 100% detection rate (Shi et al, 2018). Another study of sentinel lymph nodes by Michel et al intravenously injected ultra-small superparamagnetic nanoparticles in 20 breast cancer patients and used gadolinium-enhanced MR imaging to detect the presence of axillary lymph nodes.…”

Section: Preoperative Imagingmentioning

confidence: 99%

A path toward the clinical translation of nano‐based imaging contrast agents

Miyasato

Mohamed

Zavaleta

2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Recently, nanoparticles have evolved ubiquitously in therapeutic applications to treat a range of diseases. Despite their regular use as therapeutic agents in the clinic, we have yet to see much progress in their clinical translation as diagnostic imaging agents. Several clinical and preclinical studies support their use as imaging contrast agents, but their use in the clinical setting has been limited to off‐label imaging procedures (i.e., Feraheme). Since diagnostic imaging has been historically used as an exploratory tool to rule out disease or to screen patients for various cancers, nanoparticle toxicity remains a concern, especially when introducing exogenous contrast agents into a potentially healthy patient population, perhaps rationalizing why several nano‐based therapeutic agents have been clinically translated before nano‐based imaging agents. Another potential hindrance toward their clinical translation could be their market potential, as most therapeutic drugs have higher earning potential than small‐molecule imaging contrast agents. With these considerations in mind, perhaps a clinical path forward for nano‐based imaging contrast agents is to help guide/manage therapy. Several studies have demonstrated the ability of nanoparticles to produce more accurate imaging preoperatively, intraoperatively, and postoperatively. These applications illustrate a more reliable method of cancer detection and treatment that can prevent incomplete tumor resection and incorrect assessment of tumor progression following treatment. The aim of this review is to highlight the research that supports the use of nanoparticles in biomedical imaging applications and offer a new perspective to illustrate how nano‐based imaging agents have the potential to better inform therapeutic decisions. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging

show abstract

Dendrimer-Entrapped Gold Nanoparticles as Potential CT Contrast Agents for Localizing Sentinel Lymph Node via Indirect CT Lymphography on Rabbit Model

Cited by 4 publications

References 35 publications

New Developments in Imaging for Sentinel Lymph Node Biopsy in Early-Stage Oral Cavity Squamous Cell Carcinoma

New Developments in Imaging for Sentinel Lymph Node Biopsy in Early-Stage Oral Cavity Squamous Cell Carcinoma

CT Lymphography Using Lipiodol® for Sentinel Lymph Node Biopsy in Early-Stage Oral Cancer

A path toward the clinical translation of nano‐based imaging contrast agents

Contact Info

Product

Resources

About